Vantageview
Payments companies reported to CMS as associated with Vantageview. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vantageview, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vantageview
These are the largest totals companies reported as associated with Vantageview. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mun Hong | Cooperstown, NY | Interventional Cardiology | $47,500.00 |
| Scott Hoffman | Rochester, MN | Cardiovascular Disease | $15,750.00 |
| Irving David | Aventura, FL | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $15,318.75 |
| Mauricio Cohen | Miami, FL | Interventional Cardiology | $14,175.00 |
| Andy Kiser | Pittsburgh, PA | Surgery | $14,087.50 |
| Irfan Altafullah | Golden Valley, MN | Neurology (Psychiatry & Neurology) | $13,733.75 |
| Gregory Fontana | Thousand Oaks, CA | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $13,250.00 |
| Bao Le | College Station | Interventional Cardiology | $204.27 |
| Nezar Falluji | Phoenix, AZ | Interventional Cardiology | $126.51 |
| Jason Cohen | College Station, TX | Clinical Cardiac Electrophysiology | $126.26 |
Prescribed Vantageview?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.